These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20304805)

  • 21. Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.
    Yoo EH; Park KJ; Won HH; Park JH; Park JH; Lee ST; Kim HJ; Bang SM; Chi HS; Jung CW; Kim SH; Yun H; Sun CH; Park I; Lee S; Lee C; Merriman B; Luo R; Tan EH; Park KJ; Yoo NK; Kang JJ; Kim JW
    J Clin Lab Anal; 2016 Nov; 30(6):1061-1070. PubMed ID: 27132877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience.
    Basim Najm M; Jalal SD; Getta HA
    Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):202-209. PubMed ID: 36800830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
    Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
    Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MPL W515L mutation in Chinese patients with myeloproliferative diseases.
    Xu W; Li JY; Xia J; Zhang SJ; Fan L; Qiao C
    Leuk Lymphoma; 2008 May; 49(5):955-8. PubMed ID: 18464114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
    Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
    Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
    Milosevic Feenstra JD; Nivarthi H; Gisslinger H; Leroy E; Rumi E; Chachoua I; Bagienski K; Kubesova B; Pietra D; Gisslinger B; Milanesi C; Jäger R; Chen D; Berg T; Schalling M; Schuster M; Bock C; Constantinescu SN; Cazzola M; Kralovics R
    Blood; 2016 Jan; 127(3):325-32. PubMed ID: 26423830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.
    Moliterno AR; Williams DM; Rogers O; Spivak JL
    Blood; 2006 Dec; 108(12):3913-5. PubMed ID: 16912229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
    Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y
    Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
    Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
    J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Rare Case of Essential Thrombocythemia with Coexisting
    Jang MA; Seo MY; Choi KJ; Hong DS
    J Korean Med Sci; 2020 Jun; 35(23):e168. PubMed ID: 32537949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N
    Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
    Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
    Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
    Cazzola M; Kralovics R
    Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
    Millecker L; Lennon PA; Verstovsek S; Barkoh B; Galbincea J; Hu P; Chen SS; Jones D
    Cancer Genet Cytogenet; 2010 Feb; 197(1):1-7. PubMed ID: 20113830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
    Jones AV; Chase A; Silver RT; Oscier D; Zoi K; Wang YL; Cario H; Pahl HL; Collins A; Reiter A; Grand F; Cross NC
    Nat Genet; 2009 Apr; 41(4):446-9. PubMed ID: 19287382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
    Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
    Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.